



PCT/GB2004/002867



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 5QQ

REC'D 27 JUL 2004


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 14 July 2004

Best Available Copy

The Patent Office05JUL03 E820158/1 002806
P01/7700 0.00-0315671.8**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet, from the Patent Office to help you fill in this form)

1. Your reference

JPR172 NEWPORT

2. Patent application number

(The Patent Office will fill in this part)

0315671.8

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

Chelsea and Westminster NHS Trust
 Chelsea & Westminster Hospital
 369 Fulham Road
 London
 SW10 9NH

Patents ADP number (*if you know it*)

8667180001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Improvements In Or Relating To Organic Compounds

5. Name of your agent (*if you have one*)

Barker Brettell

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

10-12 Priests Bridge
 LONDON
 SW15 5JE

Patents ADP number (*if you know it*)

7442494003 ✓

5. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)Date of Filing
(day/month/year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)Is a statement of inventorship and of right to grant of a patent required in support of this request (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d)*

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document
Continuation sheets of this form

Description 14

Claim(s) 5

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)


Request for preliminary examination 1
(*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature


Barker Brettell

Date

03 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom James Peel Tel: 020 8392 2234

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay, please contact the Patent Office.

IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS

The present invention relates to pharmaceutical compositions suitable for vaginal or rectal administration, kits of such pharmaceutical compositions and methods of medical treatment including the vaginal or rectal administration of pharmaceutical compositions.

Induction of abortion and uterine evacuation of a failed pregnancy is associated with significant morbidity. This is because of the associated complications like uterine perforation and infection.

Prostaglandin administered preoperatively softens the cervix and reduces the trauma. In the last decade misoprostol administered vaginally has become the prostaglandin agent of choice worldwide because of its stability at room temperature. It is one of the agents that Royal College of Obstetricians and Gynaecologists (RCOG) recommends for cervical priming preoperatively.

The RCOG also recommends that all women undergoing abortion should either be treated for infections such as chlamydial and/or anaerobes or they should be screened and treated for such infections.

Genital Chlamydial trachomatis infection is most common in the youngest sexually active population (16-19 year old women and 20-24 year old men). In 1999, UK genitourinary clinics reported around 57,000 new episodes of genital infections (around 33,000 in women and 24,000 in men). This infection usually co-exists with other sexually transmitted infections, particularly gonorrhoea. Treatment options include Doxycycline or Azithromycin, but the former is associated with poor patient compliance. The use of Azithromycin is applicable to treat both men and women.

Azithromycin is unique in that it is a tissue directed antibiotic. Unlike other groups of antibiotics taken by mouth, it is absorbed rapidly from the gut to the blood stream, into the tissues and the focus of infection. A 5 recent meta-analysis of studies so far has shown that given as a single 1-gm dose orally, its efficacy to treat chlamydial infection and patient's tolerance is similar to that of a week-long course of Doxycycline. Though Azithromycin orally as a single dose is more appealing, 25% of women will experience side effects.

10

Azithromycin is licensed orally for the treatment of infections of the respiratory tract, skin and soft tissue. In gynaecology, it is licensed for uncomplicated genital infections due to chlamydia trachomatis. In 1980s, PLIVA and Pfizer were first granted patent protection in Belgium and 15 thereafter worldwide for Azithromycin. It was first registered as Sumamed in 1988.

Despite the associated high efficacy, no attempts have been made to investigate other non-invasive routes of azithromycin administration. The 20 only attempt to administer azithromycin rectally resulted in a negative study. The result being negative did not enable the group to publish this report. Based on their study they concluded that the bioavailability of azithromycin administered rectally was highly variable and low probably due to limited absorption. (George Melnik et al. Bioavailability of 25 azithromycin when delivered rectally. Presented at the 19th International congress of chemotherapy, Montreal, 1995.) This inconsistency in bioavailability meant that no other non-oral route was considered practical.

30 A solution to these problems has been sought.

According to a first aspect of the invention there is provided a pharmaceutical composition for use in the treatment and/or prevention of a pelvic tissue infection by vaginal administration which composition comprises an antibiotic and a pharmaceutically acceptable carrier or diluent.

According to a second aspect of the invention there is provided a pharmaceutical composition comprising, in admixture or separately:

- (a) an antibiotic; and
- 10 (b) a prostaglandin.

The composition according to the second aspect of the invention is preferably for use by vaginal and/or rectal administration in reducing surgical trauma resulting from gynaecological operation.

15

According to the invention there is further provided a kit comprising

- (a) an antibiotic,
- (b) a prostaglandin and
- (c) instructions for the simultaneous, sequential or separate 20 administration of (a) and (b) to a patient in need thereof.

The kit is preferably for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

25 According to the invention there is also provided a use of the composition according to the first aspect of the invention in the manufacture of a medicament for use in the treatment and/or prevention of pelvic tissue infection by vaginal and/or rectal administration.

30 According to the invention there is also provided use of a composition according to the second aspect of the invention in the manufacture of a

medicament for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

According to the invention there is provided use of a kit according to the
5 invention in the manufacture of a medicament for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

According to the invention there is further provided use of an antibiotic in
10 the manufacture of a kit according to the invention or of a composition according to the second aspect of the invention which kit or composition is for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

15 According to the invention there is further provided use of an antibiotic in the manufacture of a composition according to the first aspect of the invention for use in the treatment and/or prevention of a pelvic tissue infection by vaginal or rectal administration.

20 According to the invention there is also provided use of a prostaglandin in the manufacture of a kit according to the invention or of a composition according to the second aspect of the invention which kit or composition is for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

25

According to a third aspect of the invention there is provided a method of treating and/or preventing a pelvic tissue infection which method comprises administering vaginally or rectally a therapeutically effective amount of an antibiotic to a patient in need of such treatment.

According to a fourth aspect of the invention there is provided a method of reducing surgical trauma resulting from a gynaecological operation which method comprises administering vaginally or rectally a therapeutically effective amount of an antibiotic and of a prostaglandin to 5 a patient in need of such treatment.

It has surprisingly been found that by administering an antibiotic vaginally, significant levels of absorption into pelvic tissues are achieved. These are the tissues required to treat chlamydial infections. As in the 10 case of misoprostol, given to soften the cervix preoperatively, it is believed that altering the route of administration may enable the reduction of the side effects associated with the use of antibiotics.

This is important, as it is pertinent in two fields of public health:

- 15 1) Transcervical procedures especially induction of abortion and evacuation of uterus in failed pregnancy; and
 - 2) Prevention of infection and in particular pelvic infection and may be more so in sexually transmitted infections.
- 20 In keeping with the RCOG guidelines, women need a cervical softening agent and an antibiotic to deal with possible undetected chlamydial infection. An advantage of the composition according to the second aspect of the invention is that it reduces these two interventions to one which will improve compliance and be more convenient for the patient.

25

- The composition according to the first aspect of the invention optionally further comprises an analgesic, a non-steroidal antiinflammatory drug (NSAID), and/or a local anaesthetic drug. Examples of suitable analgesics include NSAIDs like diclofenac or agents like paracetamol. 30 Examples of suitable local anaesthetic drugs include lignocaine, bupivacaine or ropivacaine.

The antibiotic used in the invention is preferably azithromycin, but may include combination with other antibiotics for example metronidazole. The prostaglandin is preferably misoprostol, but may include cervagem.

5

The amount of the antibiotic used in the invention is preferably from 250 milligrams to 1000 milligrams of azithromycin, more preferably from 500 to 1000 milligrams. The amount of the prostaglandin used in the invention is 50 micrograms to 1000 micrograms of misoprostol, more preferably 10 from 100 to 800 micrograms.

The composition according to the second aspect of the invention preferably also includes a pharmaceutically acceptable carrier or diluent.

15 The compositions according to the invention are formulated to be suitable for vaginal and/or rectal administration. Each is optionally in the form of a tablet, pessary, suppository, cream, gel, bio-adhesive, slow release preparation and/or ointment. Examples of a pharmaceutically acceptable carrier or diluent for use in a composition according to the invention 20 include cellulose, cellulose derivatives (such as hydroxy-propyl-methylcellulose), polyethylene glycol and a vegetable oil.

Where the compositions of the present invention are in the form of a suppository, the suppository can be prepared in a conventional manner 25 using a conventional pharmaceutically acceptable carrier or diluent for the suppository.

The pharmaceutically acceptable carrier or diluent for such a suppository may include an oil and fat from animal and vegetable such as olive oil, 30 corn oil, castor oil, cotton seed oil, oil from wheat with germ, cacao oil, beef tallow, pork tallow, wool tallow, turtle tallow, squalene or a

hardened oil, an oil and fat from mineral such as Vaseline (trade mark), white soft paraffin, solid paraffin, liquid paraffin, dehydrated lanolin or silicon oil, a wax such as hohoba oil, carnauba wax, yellow bees wax or lanolin, or a partially synthetic or totally synthetic glycerin aliphatic acid ester such as mono, di or triglyceride of a middle or higher aliphatic acid such as a straight-chain saturated aliphatic acid (e.g. lauric acid, myristic acid, palmitic acid or stearic acid), or a straight-chain unsaturated aliphatic acid (e.g. oleic acid, linoleic acid or linolenic acid). The commercially available products are exemplified Witepsol [manufactured by Dynamitnobel Co.; a mixture of mono-, di- and tri-glycerides of C₁₂ - C₁₈ saturated aliphatic acid, in more detail, Witepsol H series (e.g. Witepsol H5, H12, H19, H32, H35, H37, H39, H42, H175 or H185), Witepsol W series (e.g. Witepsol W25, W31, W35 or W45), Witepsol E series (e.g. Witepsol E75, E76, E79 or E85) or Witepsol S series (e.g. Witepsol S52, S55 or S58) are included]; Pharmasol (manufactured by Nippon Oils and Fats Co.); Isocacao (manufactured by Kao Co.); SB (manufactured by Kanegafuchi Chemical Co. and Taiyo Yusi Co.; a mixture of mono-, di- and tri-glycerides of C₁₂ -C₁₈ saturated aliphatic acid, in more detail, SB-H, SB-E or SB-AM are included); Nopata (manufactured by Henkel AG.); Sapoyer (manufactured by Gattfords Co.; a mixture of mono-, di- and tri-glycerides of C₁₀ -C₁₈ saturated aliphatic acid, in more detail, Sapoyer NA, Sapoyer OS, Sapoyer AS, Sapoyer BS, Sapoyer BM or sapoyer DM are included); Masaesthalinum (manufactured by Dynamitnobel Co.; a mixture of mono-, di- and tri-glyceride of C₁₀ - C₁₈ saturated aliphatic acid, in more detail, Masaesthalinum A, AB, B, BB, BC, BCF, C, D, E or BD and Masaasthalinum 299 are included); or Migriol 810 or Migriol 812 (manufactured by Dynamitnobel Co.; a mixture of triglycerides of C₈ -C₁₂ saturated aliphatic acid, in more detail, one or more of them may optionally be incorporated when the partially synthetic or totally synthetic glycerin aliphatic acid ester as mentioned

above are incorporated). Further, other synthetic products such as polyethylene glycol or polyoxyethylene alcohol can be exemplified.

5 To the suppository may be added, if necessary, a preservative, a stabilizer, a surfactant, an aromatic, a pH adjustor or a purified water.

10 The suppository may be in various forms such as a rectal suppository which is solid at the normal temperature and melts at a body temperature; suspending the compound of the present invention in a liquid base; a soft capsule for the rectal administration; or an injection for the rectal administration.

15 The compositions and kit according to the invention are preferably for use via the vaginal route of administration. Similarly the methods of the invention preferably involve vaginal administration.

20 The invention can be used to treat infection of pelvic tissues. Pelvic tissues include the cervix, endometrium, fallopian tubes and parametrium. Infections, which can be treated by the invention, include sexually transmitted infections like chlamydia, gonorrhoea and trichomonas vaginalis.

25 The composition according to the second aspect of the invention and the kit according to the invention are preferably for use by vaginal and/or rectal administration to a patient about to undergo a genitourinary tract or lower bowel surgical operation. Similarly the method according to the fourth aspect of the invention preferably comprises administering the treatment to a patient about to undergo a gynaecological operation.
30 Examples of such operations include surgical and medical abortion,

uterine evacuation of a failed pregnancy and transcervical operations undertaken outside pregnancy.

The antibiotic and prostaglandin of the kit of the invention can be
5 administered simultaneously, sequentially or separately to reduce surgical trauma resulting from a gynaecological operation. By sequential is meant that the active ingredients (which are the antibiotic and prostaglandin) are administered one after the other. The desired effect is still achieved if they are administered separately but preferably less than about 12 hours
10 apart, more preferably less than about 2 hours apart, most preferably less than about 30 minutes apart.

The invention may optionally be used to treat a human or animal patient, especially a human or mammal patient.

15 In the kit according to the invention, the antibiotic and the prostaglandin are preferably provided in the form of pharmaceutically acceptable compositions either the antibiotic or the prostaglandin in association with a pharmaceutically acceptable carrier or diluent.

20 Examples of suitable formulations include a pessary comprising azithromycin 1000mg with a carrier such as polyethylene glycol or witepsol; a suppository formulation of azithromycin 1000mg with a carrier such as polyethylene glycol or cocoa butter or witepsol; a pessary
25 formulation of a prostaglandin (for use in the kit according to the invention) comprising misoprostol 800 microgram with a carrier such as hydroxypropyl methyl cellulose or witepsol or a free fatty acid, hard fat base; a suppository formulation of a prostglandin (for use in the kit according to the invention) comprising misoprostol 800 microgram with a carrier such as hydroxy-propyl methyl cellulose or polyethylene glycol or
30 witepsol; a pessary formulation of a prostaglandin and an antibiotic

comprising misoprostol 800 microgram and azithromycin 1000mg with a carrier such as witepsol or polyethylene glycol; a suppository formulation of a prostaglandin and an antibiotic comprising a misoprostol 800 microgram and azithromycin 1000mg with hydroxypropyl methyl cellulose or witepsol. The procedure for the preparation of such a formulation would be well known to a person of skill in the art, particularly on the basis of the disclosure in Example 1.

The invention is illustrated by the following examples, which are not intended to limit the scope of the application.

EXAMPLE 1

Example of a pessary formulation of azithromycin 500mg and misoprostol 400 mcg:

15

TABLE 1

Ingredient	Amount
AZITHROMYCIN powder	50.00g
MISOPROSTOL 200 mcg Tablets	200
WITEPSOL S55	209.00 g

A pessary formulation was prepared using the ingredients set out in Table 1. The misoprostol tablets were crushed using a blender. The resulting powder was placed in a mortar and triturated with the azithromycin. Once well mixed, the molten witepsol was added and stirred well. The mixture was then poured into one hundred 3 g moulds and allowed to set.

PILOT STUDY I

This study was done in pre-menopausal women undergoing hysterectomy for benign causes. Ten patients were given azithromycin tablets (Zithromax, Pfizer) orally or vaginally at least 18 hours preoperatively and then tissue biopsies were taken from hysterectomy samples. The

endometrial, cervical and fallopian tube levels of azithromycin were then measured using tissue pharmacokinetics using agar well diffusion bioassay method with micrococcus luteus ATCC 9341 as indicator organism, an appropriate method for this tissue directed antibiotic. (Girard AE et al.

- 5 1987. *Pharmacokinetics and in-vivo studies with azithromycin (CP-62.993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrobial Agents and chemotherapy. 31: 1948-54.*) Previous work has defined azithromycin levels greater than 2.0mg/kg tissue as significant.

10

Table 2 shows for each patient the route of administration and the time after dosage at which the serum and tissue samples were taken. The azithromycin concentrations are given for the serum samples and for the endometrial, cervical and fallopian tube tissue samples.

15

TABLE 2

No	Admin. Route	Sample time (hrs)	Serum conc. (mg/l)	Tissue concentration (mg/kg)		
				Endometrium	Cervix	Fallopian tubes
1	Oral	20.2	-	3.5	12.0	13.7
2	Oral	22.9	0.1	11.3	no sample	7.4
3	Vaginal	21.2	NDL	3.6	3.5	1.9
4	Oral	24.9	0.04	11.2	4.7	4.9
5	Vaginal	20.3	NDL	6.4	4.2	5.5
6	Vaginal	24.7	NDL	NDL	0.7	0.2
7	Vaginal	24.0	0.05	46.8	15.7	31.8
8	Oral	19.5	0.1	15.9	17.0	27.6
9	Vaginal	26.7	3.1	15.8	11.9	7.7
10	Oral	21.9	0.1	10.6	8.7	5.7

NDL = No detectable level

Patient no. 6 was not compliant with treatment. No tablets (intact or partly dissolved) were found in the vagina. She discharged herself against medical advice on day 2 post hysterectomy.

- 5 The data in Table 2 shows that administering azithromycin vaginally surprisingly results in significant levels of the antibiotic being present in pelvic tissues even 24 hours after treatment.

It is to be noted that Zithromax is formulated for oral administration and
10 therefore it is expected that use of a composition according to the first aspect of the invention formulated for vaginal administration will give improved results.

PILOT STUDY II

15

This study was done on 13 women undergoing surgical pregnancy termination. A special formulation as previously described of Azithromycin and Misoprostol was developed in a pessary format. The pessaries were administered 2-4 hours before surgical termination of the
20 pregnancy. Biopsies were obtained from the cervix and endometrium. In addition blood levels were studied. The results are shown in Table 3.

TABLE 3

Pt No	Rx time	Blood time	Biopsy time	Time after dose (hours)	Serum conc (mg/l)	Tissue conc(mg/kg) Cervix	Tissue conc(mg/kg) Endometrium
1	12.00	15.00	15.35	3.6	NDL	820.5	8.3
2	12.30	15.45	15.50	3.7	NDL	122.8	NST
3	11.50	14.25	14.30	2.7	NDL	2554.1	23.7
4	12.00	14.55	15.00	3.0	NDL	864.9	NST
5	11.55	15.30	15.35	3.7	NDL	1190.3	2.9
6	12.05	15.50	15.55	3.8	NDL	714.3	NST
7	11.15	14.05	14.15	3.0	NDL	257.9	NST
8	11.15	14.25	14.35	3.3	NDL	618.5	NST
9	11.25	14.40	14.55	3.5	NDL	629.7	NST
10	11.40	15.05	15.20	3.7	NDL	1071.7	NST
11	12.00	15.30	15.40	3.7	0.07	968.7	NST
12	11.15	14.30	14.40	3.4	NDL	8.3	NST
13	11.20	15.25	15.30	4.2	NDL	466.7	NST

NDL = No detectable level.

NST = No sample taken

These results clearly show the very high level of azithromycin in the tissues compared to the data in table II

CLAIMS

1. A pharmaceutical composition for use in the treatment and/or prevention of a pelvic tissue infection by vaginal administration which
5 composition comprises an antibiotic and a pharmaceutically acceptable carrier or diluent.
2. A composition as defined in Claim 1 comprising an analgesic, a non-steroidal anti-inflammatory drug, and/or a local anaesthetic drug.
10
3. A composition as defined in Claim 1 or Claim 2 for use in the treatment of a sexually transmitted disease.
4. A composition as defined in any one of the preceding claims
15 wherein the antibiotic includes azithromycin, optionally with metronidazole.
5. A composition as defined in any one of the preceding claims for use in the treatment of a cervix, endometrium, fallopian tube and/or
20 parametrium.
6. Use of the composition as defined in any one of the preceding claims in the manufacture of a medicament for use in the treatment and/or prevention of pelvic tissue infection by vaginal and/or rectal
25 administration.
7. A pharmaceutical composition comprising, in admixture or separately:
 - (a) an antibiotic; and
 - 30 (b) a prostaglandin.

8. A composition as defined in Claim 7 for use by vaginal and/or rectal administration, preferably vaginal administration.
9. A composition as defined in Claim 7 or Claim 8 for use in reducing surgical trauma resulting from gynaecological operation.
10. A composition as defined in any one of Claims 7 to 9 comprising a pharmaceutically acceptable carrier or diluent.
- 10 11. A composition as defined in any one of Claims 7 to 10 wherein the prostaglandin is misoprostol, optionally with cervagem.
12. A composition as defined in any one of Claims 7 to 11 wherein the antibiotic includes azithromycin, optionally with metronidazole.
- 15 13. A composition as defined in any one of Claims 7 to 12 for use in the treatment and/or prevention of a cervix, endometrium, fallopian tube and/or parametrium.
- 20 14. Use of a composition as defined in any one of Claims 7 to 13 in the manufacture of a medicament for use by vaginal and/or rectal administration in reducing surgical trauma resulting from gynaecological operation.
- 25 15. A kit comprising
(a) an antibiotic,
(b) a prostaglandin and
(c) instructions for the simultaneous, sequential or separate administration of (a) and (b) to a patient in need thereof.

16. A kit as defined in Claim 15 for use by vaginal and/or rectal administration.
17. A kit as defined in Claim 15 or 16 for use in reducing surgical trauma resulting from a gynaecological operation.
18. A kit as defined in any one of Claims 15 to 17 wherein (a) and (b) each comprise a pharmaceutically acceptable carrier or diluent.
- 10 19. Use of a kit as defined in any one of Claims 15 to 18 in the manufacture of a medicament for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.
- 15 20. Use of an antibiotic in the manufacture of a kit as defined in any one of Claims 15 to 18 or in the manufacture of a composition as defined in any one of Claims 7 to 13 which kit or composition is for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.
- 20 21. Use of an antibiotic in the manufacture of a composition as defined in any one of Claims 1 to 5 for use in the treatment and/or prevention of a pelvic tissue infection by vaginal or rectal administration.
- 25 22. Use of a prostaglandin in the manufacture of a kit as defined in any one of Claims 15 to 18 or in the manufacture of a composition as defined in any one of Claims 7 to 13 which kit or composition is for use by vaginal and/or rectal administration in reducing surgical trauma resulting from a gynaecological operation.

23. A method of treating and/or preventing a pelvic tissue infection which method comprises administering vaginally or rectally a therapeutically effective amount of an antibiotic to a patient in need of such treatment.

5

24. A method as defined in Claim 23 wherein the infection is a sexually transmitted disease.

10 25. A method as defined in Claim 23 or Claim 24 wherein the antibiotic includes azithromycin, optionally with metronidazole.

26. A method as defined in any one of the Claims 23 to 25 wherein the infected tissue is a cervix, endometrium, fallopian tube and/or parametrium.

15

27. A method of reducing surgical trauma resulting from a gynaecological operation which method comprises administering vaginally or rectally a composition comprising a therapeutically effective amount of an antibiotic and of a prostaglandin to a patient in need of such treatment.

20

28. A method as defined in Claim 27 which comprises administering the composition to a patient about to undergo a gynaecological operation.

25 29. A method as defined in Claim 28 wherein the operation includes a surgical or medical abortion, uterine evacuation of a failed pregnancy and/or a transcervical operation undertaken outside pregnancy.

30. A method as defined in any one of Claims 27 to 29 wherein the composition comprises a pharmaceutically acceptable carrier or diluent.

31. A method as defined in any one of Claims 27 to 30 wherein the prostaglandin is misoprostol, optionally with cervagem.
32. A method as defined in any one of Claims 27 to 31 wherein the antibiotic includes azithromycin, optionally with metronidazole.
5
33. A method as defined in any one of Claims 23 to 32 wherein the patient is a human or animal patient, especially a human or mammal patient.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.